Eiger BioPharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Eiger Biopharmaceuticals

06/05/2022 15:04

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of 64 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 64 cents per share.
    * Revenue fell 26.7% to $2.67 million from a year ago; 
analysts
expected $4.04 million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of 64 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.2%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Eiger BioPharmaceuticals Inc shares had fallen by 25.9%
this
quarter and gained 18.5% so far this year.
    * The company reported a quarterly loss of $22.64 million.
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $29.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 6 at 02:04 p.m.  ​All
figures in US dollars unless otherwise stated